Articles By Olga Petryna, MD
Statins Improve Survival in Ankylosing Spondylitis
Systemic inflammation (from underling inflammatory polyarthritis) clearly accelerates atherosclerosis with a resultant increase risk of cardiovascular disease.
Read Article
Breastfeeding Rates Lower in Lupus
It is a common practice for rheumatologists to discuss medication-related teratogenicity and disease implications in case of pregnancy. Yet, discussion of breastfeeding are often omitted.
Read Article
Bone Turnover Markers in Practice: A Guide for the Rheumatologist
Bone turnover markers (BTMs) have been eyed for decades as potential monitoring tools in osteoporosis.
Read ArticleResponder Criteria for Nonpharmalogical Treatment of Fibromyalgia.
Because of the subjective nature of fibromyalgia symptoms, tools for monitoring of disease activity and/or treatment assessment tools to evaluate effectiveness of nonpharmacological modalities are difficult to develop.
Read ArticleGuselkumab for Active Psoriatic Arthritis
A double-blind, placebo-controlled, multicenter study aimed to evaluate efficacy and safety of a fully human monoclonal anti IL-23 antibody guselkumab, in patients with active psoriatic arthritis.
Read Articlelxekizumab Performance in TNF Nonresponders Phase 3 Trial
Lxekizumab performs well in TNF nonresponders phase 3 trial.With more IL17 inhibitors becoming available for treatment of seronegative spondyloarthropathies, the question of efficacy and safety in different clinical scenarios arises. The phase 3 PsA SPIRIT-P2 trial involving 363 patients with PsA who failed or could not tolerate 1-2 TNFi randomized patients into 3 groups: PBO, IXE 80 mg q 2 weeks and IXE 80 mg q 4 weeks. Normal 0 false false false EN-US X-NONE X-NONE /* Style Definitions */ table.MsoNormalTable {mso-style-name:"Table Normal"; mso-tstyle-rowband-size:0; mso-tstyle-colband-size:0; mso-style-noshow:yes; mso-style-priority:99; mso-style-parent:""; mso-padding-alt:0cm 5.4pt 0cm 5.4pt; mso-para-margin:0cm; mso-para-margin-bottom:.0001pt; line-height:115%; mso-pagination:widow-orphan; font-size:11.0pt; font-family:Arial; color:black;}
Read ArticleTreat-to-Target in Spondyloarthropathies
Today's session, Treat to target in axSpA: reality or utopia?, was opened with a presentation by Dr. Jurgen Braun (Herne, Germany), who masterfully reintroduced us to the treat-to-target concept in spondyloarhtropathies.
Read Article
EULAR/EFORT Taskforce on the Management of Fragility Fractures
The morbidity associated with osteoporosis-related fragility fractures imposes tremendous socioeconomic and medical impact on patients and society.
Read Article
High Level Rheumatoid Responses to the GM-CSF inhibitor Mavrilimumab
Despite recent advances in treatment of rheumatoid arthritis (RA), MANY patients on existent biological therapy fail to achieve remission. Therapies with novel mechanisms of actions, great efficacy and well balanced safety profile remain an unmet need.
Read Article
An Integrated Analysis of Tofacitinib Safety
Since its US approval in 2012, tofacitinib has become a widely used treatment for rheumatoid arthritis (RA). Whether you're impressed with its efficacy, or distressed with its side effects, its track record is voluminous and has been recently reviewed.
Read Article